Literature DB >> 10468908

Effect of acute high dose dobutamine administration on serum thyrotrophin (TSH).

E Lee1, P Chen, H Rao, J Lee, L A Burmeister.   

Abstract

OBJECTIVE: The interpretation of thyroid function tests in the setting of severe illness is often complicated by concomitant drug administration which may independently produce changes in thyroid hormone concentrations or even secondary hypothyroidism. Although the effects of dopamine on TSH are well established, the effects of dobutamine, another drug commonly used in the setting of severe illness, on TSH are unknown. The aim of the study was to establish the effect(s) of acute high dose dobutamine on serum TSH concentration. DESIGN AND PATIENTS: Thirty subjects undergoing dobutamine stress echocardiogram were compared to twenty controls. Serum TSH was determined between the hours of 0800 and 1000 h at baseline, at maximum dobutamine infusion (20-50 micrograms/kg/min and 15 minutes after stopping dobutamine. MEASUREMENTS: Serum TSH concentration was measured using a third generation chemiluminescent assay.
RESULTS: TSH concentration decreased with time in both dobutamine and control subjects and there was an additional statistically significant effect of dobutamine treatment to decrease TSH. TSH concentration remained within the normal range in all subjects who started with normal TSH concentration and remained above normal in the three dobutamine-treated subjects with elevated TSH at baseline. The dobutamine-associated decrease in TSH was still present 15 minutes after discontinuing dobutamine.
CONCLUSIONS: These results indicate that acute high dose dobutamine lowers TSH by an unknown mechanism. Additional study with prolonged dobutamine infusion is needed to establish the steady state level and physiological consequences of dobutamine-inhibited TSH.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468908     DOI: 10.1046/j.1365-2265.1999.00678.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Dopamine versus dobutamine in very low birthweight infants: endocrine effects.

Authors:  Luca Filippi; Marco Pezzati; Chiara Poggi; Sauro Rossi; Alessandra Cecchi; Cristina Santoro
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-02-28       Impact factor: 5.747

Review 2.  Hyperthyroidism.

Authors:  Mala Sharma; Wilbert S Aronow; Laxesh Patel; Kaushang Gandhi; Harit Desai
Journal:  Med Sci Monit       Date:  2011-04

3.  A case of masked toxic adenoma in a patient with non-thyroidal illness.

Authors:  Eun Ae Cho; Jee Hee Yoon; Hee Kyung Kim; Ho-Cheol Kang
Journal:  BMC Endocr Disord       Date:  2014-01-02       Impact factor: 2.763

4.  Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level.

Authors:  Wona Choi; Yoon-Sik Yang; Dong-Jin Chang; Yeon Woong Chung; HyungMin Kim; Soo Jeong Ko; Sooyoung Yoo; Ji Seon Oh; Dong Yoon Kang; Hyeon-Jong Yang; In Young Choi
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

5.  Association of hypothyroidism with outcomes in hospitalized adults with COVID-19: Results from the International SCCM Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry.

Authors:  Marija Bogojevic; Vikas Bansal; Vishwanath Pattan; Romil Singh; Aysun Tekin; Mayank Sharma; Abigail T La Nou; Allison M LeMahieu; Andrew C Hanson; Phillip J Schulte; Neha Deo; Shahraz Qamar; Simon Zec; Diana J Valencia Morales; Nicholas Perkins; Margit Kaufman; Joshua L Denson; Roman Melamed; Valerie M Banner-Goodspeed; Amy B Christie; Yasir Tarabichi; Smith Heavner; Vishakha K Kumar; Allan J Walkey; Ognjen Gajic; Sumit Bhagra; Rahul Kashyap; Amos Lal; Juan Pablo Domecq
Journal:  Clin Endocrinol (Oxf)       Date:  2022-02-18       Impact factor: 3.523

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.